Overview page

Domperidone, commonly marketed abroad under brand names such as Motilium, is a dopamine D2 and D3 receptor antagonist with prominent effects on the gastrointestinal tract. It is used in many countries as a prokinetic to speed gastric emptying and as an antiemetic to reduce nausea and vomiting.

Key ideas at a glance:

• Domperidone as the active ingredient.
• Often found as 10 mg tablets in markets outside the United States.
• Typical clinical roles: symptomatic relief of delayed gastric emptying, reduction of nausea and vomiting.

Attention: important: The US Food and Drug Administration has not approved domperidone for routine marketing in the United States. For information on how patients and prescribers may legally obtain it, see The status of legal and regulatory policy affairs in the United States. For safety details, consult Safety guidelines and contraindication.

Common places of use

Where it is legally available, domperidone is prescribed for diverse upper gastrointestinal complaints and for control of nausea. Conventional indicators include:

• Symptoms of gastroparesis or delayed gastric emptying, such as persistent nausea, early fullness, and poor tolerance of meals.
• Management of noncentral causes of nausea and vomiting, for example postoperatively or with certain medications.
• Short-term adjunctive antiemetic support for selected chemotherapy or radiation protocols, under specialist oversight.
• Used by clinicians to improve gastric motility when preparing patients for specific diagnostic imaging.

All treatment choices should be made by a licensed clinician. See Legal and regulatory terrain in the United States for US-specific access options.

Dose and administration directions

Domperidone should only be taken under medical supervision. Because it is not widely available in the United States, the dosing information below reflects international practice and is provided for informational purposes only.

General administration guidance:

• Timing: Oral doses are commonly taken 15 to 30 minutes before meals to enhance the prokinetic effect. A single dose at bedtime can be used for nocturnal symptoms.
• Dose skipped in schedule: When a dose is missed, take it when you remember if there is enough time before the next dose. Do not double doses to compensate.
• Formulation issues: Some tablet products contain lactose or other excipients. People with lactose intolerance or specific absorption disorders should discuss substitute options with their prescriber or pharmacist.

Typical international dosing examples

• Acute nausea or vomiting:
  • Adults: regimens reported in practice include 20 mg taken three to four times daily (for instance, two 10 milligram tablets each dose).
  • Youngsters 5 to 12 years: doses around 10 mg three to four times daily have been used under pediatric consistent guidance.
• Chronic functional dyspepsia or motility disorders:
  • Adults: a common approach is 10 mg three times daily, adjusted by the prescribing clinician.
  • The younger generation 5 to 12 years: lower pediatric doses such as 5 mg three times daily may be selected by a pediatric specialist.

Do not use usual tablet strengths in children under 5 years of age or in small children weighing less than about 35 kg unless an appropriate liquid preparation and pediatric dosing plan are supplied. Patients with significant renal impairment may need reduced dosing frequency because of slower clearance. For best practices for performance monitoring, see Wellbeing and factors that make therapy unsuitable.

Secure storage refers to the act of keeping items or data for future use.

• Keep tablets at 20 to 25 degrees C (68 to 77 degrees F), away from excessive heat.
• Protect the product from direct sunlight, moisture, and strong odors to preserve stability.
• Store all medicines out of the reach of children and pets and, when possible, keep them in their original packaging.

Safety awareness and contraindicating factors in clinical decisions

Before we start domperidone, have a frank discussion with a clinician about the potential benefits and risks. The medication should be avoided except under specific medical authorization in the following situations:

Absolute therapy is not indicated due to these conditions

• Known allergy to domperidone or to any inactive ingredient in the formulation.
• Pregnancy, unless the treating clinician judges that the potential benefit outweighs the risk.
• Use solely to increase breast milk output is discouraged in the United States because of documented cardiac safety concerns.
• Conditions such as gastrointestinal bleeding, obstruction, or perforation where increased motility would be harmful.
• Prolactin-secreting pituitary tumors or situations where increased prolactin is contraindicated.
• Severe hepatic insufficiency.
• Known prolonged QT interval, significant underlying heart disease, or uncorrected low serum potassium or magnesium.

Exercise extra caution in patients with renal dysfunction, fluid retention, or in those taking interacting medications. When clinicians choose to use domperidone, baseline and periodic ECGs and electrolyte testing are often recommended, particularly in patients with cardiac risk factors. See Interactions with others between medicines for drugs that raise cardiac risk.

Pregnancy and lactation: Limited clinical data are available. Small amounts of the drug can appear in breast milk. In the United States, health authorities advise against using domperidone only for lactation induction because of cardiac safety concerns; discuss an alternate paths in consultation with your clinician.

Medication a mutual exchange of ideass create opportunities for collaboration. pose risks

Domperidone interacts with a range of medicines that can reduce its benefit or increase the risk of harmful consequences, especially cardiac arrhythmias. Provide your clinician and pharmacist with a complete list of your current medications.

Drugs that may lessen prokinetic efficacy

• Anticholinergic agents such as oxybutynin, tolterodine, hyoscine, and propantheline.
• Opioid analgesics like morphine and codeine, which slow gut motility.
• Certain Parkinson disease anticholinergics including trihexyphenidyl.

Drugs that increase domperidone exposure or cardiac risk

• Potent CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, erythromycin, and some HIV protease inhibitors can raise domperidone levels.
• Certain calcium channel blockers that affect CYP3A4, for example verapamil and diltiazem.
• Other agents that prolong the QT interval: selected antiarrhythmics, some antipsychotics, and particular antibiotics including some fluoroquinolones.

These lists are not exhaustive. A prescriber may avoid domperidone or implement enhanced cardiac real time monitoring if you take any interacting medicines. For real time monitoring and contraindication details, see Safety info for reasons to avoid this medication.

Expected undesired reactions

Reported harmful bodily effects range from mild gastrointestinal complaints to rare but serious cardiac events. Notify your healthcare provider promptly if concerning symptoms occur.

• Mild to moderate:
  • Experiencing abdominal discomfort, cramping, or diarrhea.
  • A rash of the skin or hypersensitivity reactions in susceptible individuals.
• Not commonly seen but clinically significant:
  • Increased prolactin with potential galactorrhea, breast changes, or menstrual disturbances.
  • Loss of libido or erectile dysfunction in some men.
  • Extrapyramidal symptoms including tremor or involuntary movements that require urgent assessment.

Cardiac safety: Domperidone has been linked to QT interval prolongation and rare ventricular arrhythmias, particularly at high doses or when combined with interacting drugs. Seek immediate care for palpitations, fainting, severe dizziness, or syncope. This document does not replace personalized medical advice.

Replacement options and medicines that resemble one another in effect

Because domperidone is not FDA approved, US clinicians often choose from approved agents with known safety profiles. Options that may be considered include:

• Metoclopramide (Reglan) - a dopamine antagonist used for gastroparesis; its long term use is limited by the risk of tardive dyskinesia.
• Ondansetron (Zofran) - a 5-HT3 antagonist widely used for chemotherapy, postoperative, and radiation-related nausea; it does not increase gastric emptying.
• Prochlorperazine - a dopamine antagonist often used for acute nausea.
• Promethazine - an antihistamine with antiemetic effects, useful for motion sickness and some nausea syndromes.
• Erythromycin - an antibiotic that can act as a motilin receptor agonist and be used short term as a prokinetic, though tolerance and subtle engagement and communications can reinforce culture. limit prolonged use.
• Prucalopride - a selective 5-HT4 agonist approved for chronic constipation and sometimes used off-label by specialists for specific motility disorders.

Your clinician will weigh effectiveness, safety, comorbidities, and cost when suggesting ancillary choices. For approximate expense comparisons, see Prices in America (USD).

USA prices in USD

Costs vary by pharmacy, geographic region, insurance coverage, and whether domperidone is provided through a compounding pharmacy or an FDA expanded access IND. The figures below are illustrative estimates in US dollar totals.

• Domperidone obtained via a physician-authorized expanded access IND or prepared by a compounding pharmacy: roughly $0.40 to $1.50 per 10 mg capsule equivalent. A typical 30-day supply may therefore cost approximately $36 to $360 depending on dose, frequency, compounding fees, and shipping.
• Metoclopramide 10 mg unit tablets (generic): approximately $4 to $20 for 30 tablets.
• Ondansetron 4 mg or 8 mg tablets (generic): about $10 to $50 for 30 tablets depending on dose and brand.
• Prochlorperazine 5 mg or 10 mg (generic): approximately $4 to $15 for 30 tablets.
• Promethazine 12.5 mg unit or 25 mg (generic): typically $5 to $20 for 30 tablets.
• Erythromycin used short term as a prokinetic: commonly $10 to $40 depending on formulation and quantity.

Insurance coverage, coupons, and patient assistance programs can reduce out-of-pocket costs. Because domperidone is not commercially marketed in the United States, expect additional administrative charges from clinicians or compounding pharmacies; setup or documentation fees may range from about $20 to $150 depending on provider policies.

The laws and regulations machinery in the United States

Key the field of legal and regulatory affairs points for US patients and prescribers:

• Domperidone is not approved by the FDA for any indication in conjunction with therefore is not sold as a marketed product in the United States.
• A common legal pathway for access is a physician-sponsored FDA expanded access Investigational New Drug (IND) application. That process requires medical justification, informed consent, safety vigilant monitoring (for example ECGs and electrolytes), and regulatory paperwork.
• Some compounding pharmacies may prepare domperidone for named patients when a clinician provides an appropriate IND and documentation. This is not equivalent to over-the-counter availability.
• Personal importation of domperidone from overseas suppliers is generally restricted; shipments may be detained or refused by US Customs and also the FDA. Do not attempt to import the medicine without explicit regulatory permission.
• The FDA has issued communications advising against use of domperidone for lactation induction because of reported cardiac safety signals.

If you believe domperidone is medically necessary, discuss the FDA expanded access IND pathway with a US-licensed clinician. That clinician can explain the application process, performance monitoring requirements, supportive complementary therapies, and likely timelines. For safety requirementsan in depth review Safety guidelines and conditions under which this therapy should be avoided and Drug the interaction between participants considerations.

The most common questions

• Is Motilium available over the counter in the United States?
  • No. Domperidone (Motilium) is not FDA approved in the United States and so is not available over the counter. Limited access may be possible only through a physician-sponsored expanded access IND program. See The regulatory and legal climate in the United States.
• Can I order domperidone from another country and have it shipped to the US?
  • Generally no. Personal importation is restricted and foreign shipments may be detained by US Customs as well as the FDA. Advise to seek counsel your healthcare provider about legal pathways such as the IND process instead of attempting to import medication. See American regulatory and legal considerations architecture landscape.
• What should I do in case I miss a dose?
  • Take the i did not take my prescribed dose as soon as you remember unless the next scheduled dose is near. Do not double your next dose. For more information, consult How to take medications safely and determine dosage directions.
• Who should avoid domperidone?
  • People with significant cardiac disease, known prolonged QT interval, severe liver impairment, or those taking strong CYP3A4 inhibitors should not use domperidone unless specifically authorized by a specialist. See Safety instructions and conditions under which this therapy should be avoided see details for more knowledge.

This page is intended for general educational use and does not replace personalized medical or legal advice. Always follow the guidance of your health care provider and consult current FDA resources before making decisions about treatment or medication importation.